Tricare covers GLP-1 medications in 2026, but coverage depends on the specific drug, the FDA indication, and the patient category.

Short version: rats develop thyroid C-cell tumors on long-term tirzepatide, which is why the FDA requires a boxed warning.

Tirzepatide moves more labs than semaglutide because it hits two receptors, GLP-1 and GIP. HbA1c drops harder. Fasting glucose drops harder.

Introduction The current state of evidence as of 2026: no human data has linked semaglutide to increased cancer risk, and some studies show reduced…

Semaglutide changes several blood test results, and most of those changes are the point of the drug.

Yes, Ozempic mildly increases urination in many patients, especially during active weight loss.

The honest answer is no in the short term, yes in the medium term. Mounjaro (tirzepatide) is not a stimulant.

Introduction Medicare’s GLP-1 coverage in 2026 is a patchwork of yes, no, and “only if.” The short answer: Medicare covers GLP-1s for type 2…

Medicaid coverage of GLP-1 medications in 2026 depends entirely on your state and your diagnosis.